Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

LAB Research adopts shareholder rights plan

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

LAB Research

On February 8, 2007, LAB Research Inc. announced that its Board of Directors had adopted a Shareholder Rights Plan to ensure the fair treatment of shareholders in connection with any take-over offer for the Corporation, and to provide the Board of Directors and shareholders with additional time to fully consider any unsolicited take-over bid. The Rights Plan will provide the Board of Directors more time to pursue, if appropriate, other alternatives to maximize shareholder value. The Rights Plan has conditionally been approved by the Toronto Stock Exchange and is subject to approval by shareholders at the 2007 annual meeting of the shareholders of the Corporation. If approved, it will have an initial term of three years. LAB Research is a non-clinical contract research organization (CRO) that provides contract research services to the pharmaceutical, biotechnology and agro-chemical market. The Corporation was advised in the preparation of this Rights Plan by a team from Fasken Martineau comprised of Michel Boislard and Marie-Josée Vincelli.

Team

    Subscribe

    Receive email updates from our team

    Subscribe